Glycoconjugates |
| Neoglycolipids
Neoglycoproteins |
| Blood Group & Lewis Antigen Neoglycoproteins |
| Catalog Number |
Product Name |
|
Pack Size |
| NGP0302 |
Lewisx-BSA (3 atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP0307 |
2'-Fucosyllactose-BSA (2'FL-BSA) (3 atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP0501 |
Lacto-N-fucopentaose II-BSA (3 atom spacer)
Lewisa trisaccharide, but with an additional 'lactose' spacer |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP0502 |
Lacto-N-fucopentaose III-BSA (3 atom spacer)
Lewisx trisaccharide, but with an additional 'lactose' spacer |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP0503 |
Lacto-N-fucopentaose I-BSA (LNFPI-BSA) (3 atom spacer)
Blood Group H (type I) linked b1-3 on to a lactose spacer |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP0601 |
Lacto-N-difucohexaose I-BSA (LNDFHI-BSA) (3 atom spacer)
The Lewisb antigen linked to a lactose spacer. Structure recognised
by Helicobacter pylori in binding to human gastric epithelium (Borén
et al (1993) Science 262 1892-4). |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP1305 |
Blood Group A-trisaccharide BSA (20-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP1323 |
Blood Group B-trisaccharide BSA (20-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP2340 |
Globotriose-HSA (3 atom spacer)
Gala1-4Galb1-4Glc-HSA |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| Core Structure Neoglycoproteins |
| NGP0201 |
N-Acetyllactosamine-BSA (3-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP1201 |
N-Acetyllactosamine-BSA (14-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP1336 |
a1-3,a1-6 Mannotriose-BSA (14-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| Mononsaccharide Neoglycoproteins |
| NGP1101 |
N-Acetylglucosamine-BSA (14-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP1104 |
N-Acetylgalactosamine-BSA (14-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP1105 |
L-Fucose-BSA (14-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP1106 |
L-Rhamnose-BSA (14-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP1107 |
D-Galactose-BSA (14-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP1108 |
D-Mannose-BSA (14-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP1109 |
L-Arabinose-BSA (14-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP1110 |
D-Xylose-BSA (14-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| Tumor Antigen Neoglycoproteins |
| NGP2208 |
T-Antigen-HSA
Galb1-3GalNAc-HSA (3-atom spacer)
Carbohydrate disaccharide component of T-antigen or Thomsen Friedenreich antigen
associated with tumor cells .Springer G.F (1984) Science 224: 1198 |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP2103 |
Tn-Antigen-HSA (7 atom spacer)
GalNAca1-O-(Ser-N-Ac-CO)-Spacer-NH-HSA
The Tn antigen has been shown to be expressed in over 70% of lung, colon
and stomach carcinomas. Itzkowitz et al, (1989) Cancer Res. 49: 197 |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| Sialylated Neoglycoproteins |
| NGP0301 |
3' Sialyl-N-acetyllactosamine-BSA (3-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP1301 |
3'-Sialyl-N-acetyllactosamine-BSA (14-atom spacer)
Will act as an acceptor for L-fucose with many fucosyl transferases to give a SLex neoglycoprotein. |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP0403 |
3'-Sialyl Lewisx-BSA (3-atom spacer)
Caused inhibition of binding of carcinoembryonic antigen to E-Selectin (ELISA assay). |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP2403 |
3'-Sialyl Lewisx-HSA (3-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP0405 |
3'-Sialyl-3-Fucosyl-Lactose-BSA (3-atom spacer) |
|
0.25 mg 0.5 mg 1 mg |
| NGP1403 |
3'-Sialyl Lewisx-BSA (14-atom spacer) |
|
0.25 mg 0.5 mg 1 mg |
| Gal a1-3 Gal Series Neoglycoproteins |
| NGP0203 |
Gala1-3Gal-BSA (3-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP1203 |
Gala1-3Gal-BSA (14-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP2203 |
Gala1-3Gal-HSA (3-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP3203 |
Gala1-3Gal-HSA (14-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP0334 |
Gala1-3Galb1-4GlcNAc-BSA (3-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP1334 |
Gala1-3Galb1-4GlcNAc-BSA (14-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP2334 |
Gala1-3Galb1-4GlcNAc-HSA (3-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP3334 |
Gala1-3Galb1-4GlcNAc-HSA (14-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| Gal a1-3 Gal Analogue Neoglycoproteins |
| NGP0330 |
Gala1-3Galb1-4Glc-BSA (3-atom spacer)
Linear B-6 trisaccharide-BSA
Effective Ligand for IgG Anti-Gal Antibodies
|
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP2330 |
Gala1-3Galb1-4Glc-HSA (3-atom spacer)
Linear B-6 trisaccharide-HSA
Effective Ligand for IgG Anti-Gal Antibodies |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP0333 |
Gala1-3Galb1-3GlcNAc-BSA (3-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP2333 |
Gala1-3Galb1-3GlcNAc-HSA (3-atom spacer) |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP2335 |
Gala1-3Galb1-4(3-deoxyGlcNAc)-HSA (3-atom spacer)
Specifically binds to IgM Anti-Gal Antibodies |
|
0.25 mg 0.5 mg 1 mg 5 mg |
| NGP2336 |
Gala1-3Galb1-4(6-deoxyGlcNAc)-HSA (3-atom spacer)
Specifically binds to IgM Anti-Gal Antibodies |
|
0.25 mg 0.5 mg 1 mg 5 mg |
